Log In
Print
BCIQ
Print
Print this Print this
 

Isentress, raltegravir (formerly MK-0518)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionHIV integrase inhibitor
Molecular Target HIV integrase
Mechanism of ActionHIV integrase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication Details treat HIV-1 infection in patients >=4 weeks old; Treat HIV infection; Treat HIV infection in treatment-naïve patients; Treat HIV-1 infection in children and adolescents ages 2-18; Treat HIV-1 infection in treatment-naïve patients
Regulatory Designation

Australia - Orphan Drug (Treat HIV-1 infection in children and adolescents ages 2-18)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today